These Analysts Revise Their Forecasts On Chewy Following Q2 Results
Source: benzinga.com

Chewy reported Q2 sales growth of 7.3% to $3.33 billion, slightly below the $3.361 billion consensus estimate, while adjusted EPS of $0.36 matched expectations. The company raised fiscal 2026 revenue guidance to $13.46 billion-$13.57 billion and lifted its adjusted EBITDA margin outlook to 6.7%-6.8%, but its Q3 sales midpoint of about $3.34 billion is only marginally above consensus. Shares fell 1.5% premarket as Evercore downgraded the stock and Baird and Rosenblatt cut price targets.
Analysis
CHWY’s issue is not a demand collapse but the market’s willingness to pay for modest top-line beats while management funds growth initiatives. The guide implies limited near-term operating leverage beyond the existing profitability trajectory, leaving the stock vulnerable to estimate-cut cycles if revenue conversion remains soft. In consumer internet/retail, a sequence of small sales misses typically matters more than a narrow EBITDA-margin uplift because it calls into question customer-acquisition efficiency and the terminal growth rate embedded in valuation.
The competitive read-through is selectively negative for pet retail rather than broad consumer discretionary. Chewy’s recurring-revenue model should cushion earnings versus discretionary e-commerce peers, but weaker incremental spending would favor value-oriented mass merchants with pet exposure, notably WMT and COST, whose store traffic and basket economics can absorb pet-category price competition. Over the next 1-3 months, analyst model resets and any reduction in active-customer or autoship growth are the key downside catalysts; over 6-18 months, sustained margin expansion without reaccelerating sales would support a rerating only if it demonstrates lower fulfillment and marketing intensity rather than deferred investment.
The contrarian setup is that a modest post-report decline may be insufficient to establish a durable short if recurring revenue and customer metrics remain intact: the earnings downside is bounded by improving profitability and a relatively asset-light balance sheet. The bearish thesis is falsified by a clean return to revenue outperformance next quarter, coupled with EBITDA margin above the upper end of guidance; the bull case is falsified if sales guidance is reduced again or if margin gains require a material slowdown in growth investment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.18
Ticker Sentiment
Key Decisions for Investors
- Maintain a neutral-to-underweight CHWY stance for the next 1-3 months; do not add on a modest post-earnings dip until active-customer, autoship penetration, and gross-margin disclosure confirm that the revenue softness is not broadening.
- For a relative-value expression, consider long WMT versus short CHWY in equal-dollar size over the next quarter: WMT has greater ability to monetize pet-category traffic across the basket, while CHWY carries greater sensitivity to e-commerce growth deceleration. Exit the pair if CHWY’s next revenue growth materially reaccelerates and its EBITDA margin exceeds the high end of guidance.
- Avoid directional CHWY options until implied volatility and the next reporting-date premium are reviewed; the current information does not establish that a volatility purchase has positive expected value.
- Set an earnings watch trigger: a second consecutive revenue miss or a full-year sales-guide reduction would support increasing the CHWY underweight; conversely, evidence that margin expansion is driven by fulfillment efficiency rather than lower marketing spend would justify covering.
More News
- 3 Stocks to Buy as the AI Trade Sputters
- Airbnb vs. Chewy: Do Pets or Places Power One Stock More than the Other?
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Biotech stocks are surging. How investors can play the new drug innovation boom
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Braskem creditors, shareholders near deal on $11bn debt restructuring
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations
- Selecting an AI Research Platform for Institutional Investors